Comunicati Stampa


Method to improve the diagnostic accuracy of PSA-IgM published in Cancer Biomarkers

Cancer Biomarkers publishes a collaborative study between Xeptagen and the Unit of Urology, Surgical Department, University-Hospital of Parma, on the improvement of the diagnostic accuracy of PSA-IgM. The paper entitled "A novel algorithm for the prediction of prostate cancer in clinically suspected patients" describes iXip, a new predictive probability for prostate cancer, based on the determination of PSA-IgM in conjuction with other clinical parameters. iXip is intended as a guide in postscreening diagnostic evaluations in order to reduce many expensive and injurious prostate biopsies unnecessarily performed. The identification of subpopulations according to the prostate cancer risk may guide the urologist in making clinical decisions before recommending a prostate biopsy.